Clinical Trial Update: Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating adding an antibody to standard chemoradiation, followed by one year of antibody therapy, for patients with unresectable s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 | Phase 3 | Status: ACTIVE_NOT_RECRUITING